|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Hematologic malignancy
Pembrolizumab
for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
Cancer Res Treat.
2024;56(2):681-687. Published online November 10, 2023 DOI:
https://doi.org/10.4143/crt.2023.1042
Lung and Thoracic cancer
A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus
Pembrolizumab
in Patients with Stage IV Non-Small Cell Lung Cancer
Eo Jin Kim, Yong-Hee Cho, Dong Ha Kim, Dae-Hyun Ko, Eun-Ju Do, Sang-Yeob Kim, Yong Man Kim, Jae Seob Jung, Yoonmi Kang, Wonjun Ji, Myeong Geun Choi, Jae Cheol Lee, Jin Kyung Rho, Chang-Min Choi
Cancer Res Treat.
2022;54(4):1005-1016. Published online December 3, 2021 DOI:
https://doi.org/10.4143/crt.2021.986
Web of Science 6
Crossref 5
Gastrointestinal cancer
Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors
Jwa Hoon Kim, Bokyung Ahn, Seung-Mo Hong, Hwoon-Yong Jung, Do Hoon Kim, Kee Don Choi, Ji Yong Ahn, Jeong Hoon Lee, Hee Kyoung Na, Jong Hoon Kim, Yong-Hee Kim, Hyeong Ryul Kim, Hyun Joo Lee, Sung-Bae Kim, Sook Ryun Park
Cancer Res Treat.
2022;54(2):505-516. Published online June 23, 2021 DOI:
https://doi.org/10.4143/crt.2020.1198
Web of Science 15
Crossref 16
Efficacy and Safety of
Pembrolizumab
in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Res Treat.
2020;52(2):594-603. Published online December 18, 2019 DOI:
https://doi.org/10.4143/crt.2019.493
Web of Science 48
Crossref 46
Comparison of Efficacy of
Pembrolizumab
between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kim
Cancer Res Treat.
2019;51(2):611-622. Published online July 20, 2018 DOI:
https://doi.org/10.4143/crt.2018.191
Web of Science 64
Crossref 60
Pembrolizumab
for Refractory Metastatic Myxofibrosarcoma: A Case Report
Haa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Lee
Cancer Res Treat.
2018;50(4):1458-1461. Published online January 22, 2018 DOI:
https://doi.org/10.4143/crt.2017.529
Web of Science 13
Crossref 12
1
Journal Impact Factor 4.6
> Browse Articles > Search
